Treatment of hepatic steatosis related oligo-ovulation

A technology of visceral fat and liver, applied in the field of treatment or prevention of PCOS and PCOS-like symptoms

Pending Publication Date: 2018-11-09
UNIVERSITE CATHOLIQUE DE LOUVAIN +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

9- 12 However, these data are of limited utility as the drugs tested (such as flutamide and cyproterone acetate) are not available in many countries

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of hepatic steatosis related oligo-ovulation
  • Treatment of hepatic steatosis related oligo-ovulation
  • Treatment of hepatic steatosis related oligo-ovulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1: Treatment with low dose spironolactone pioglitazone metformin for adolescent girls / young women with hyperinsulinemic hyperandrogenism.

[0075] method

[0076] Research plan and object

[0077]Table 1 summarizes the randomized, single-centre, open-label study plan over 24 months.

[0078] The study subjects included 36 Catalan girls who fulfilled four selection criteria for hirsutism (Freeman-Galway scale score >8), oligomenorrhea (menstrual interval >45 days), gynecological age ( or time since menarche) > 2.0 years, and no sexual activity (not requiring contraception).

[0079] The girls were recruited between January 2013 and May 2014 at the Department of Adolescent Endocrinology, Sant Joan of Arc University Hospital, Barcelona, ​​Spain (matching flowchart; Figure 6 ). Recruitment was biased against overweight / obesity because, in our setting, overweight / obese adolescent girls were primarily referred to obesity rather than adolescent endocrinology.

[...

Embodiment 2

[0118] Embodiment 2: tablet

[0119] For the manufacture of the tablets, the active substances spironolactone, metformin and pioglitazone are mixed with polyvinylpyrrolidone. Low shear wet granulation is performed and the resulting granules are dried and milled. The remaining excipients (croscarmellose sodium, microcrystalline cellulose, magnesium stearate and polyvinyl alcohol) were mixed with the milled granules and mixed together with the lubricant polyvinyl alcohol. Finally the mixture was compressed into tablets having the following composition.

[0120] The prepared tablet core comprises:

[0121] tablet core

Quantity / mg

Features

core

spironolactone

50

active ingredients

pioglitazone

7.5

active ingredients

Metformin

850

active ingredients

Polyvinylpyrrolidone

55

Adhesive

Croscarmellose Sodium

30

Thinner

microcrystalline cellulose

70

disintegrant

Ma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and / or visceral fat, such as polycystic ovary syndrome in adolescent girlsor women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.

Description

technical field [0001] The present invention relates to a method and composition for treating or preventing PCOS and PCOS-like symptoms, including the treatment or prevention of hypofertility caused by low ovulation rate, which is related to puberty girls or women of childbearing age with associated with hepatic steatosis. Background technique [0002] Hyperinsulinemic androgen excess, the symptom leading to a diagnosis of polycystic ovary syndrome (PCOS), is the most common cause of hirsutism, acne, seborrhea, and menstrual irregularities in adolescent girls. 1 The term 'hyperinsulinemic androgen excess' could replace the term 'polycystic ovary syndrome', which was criticized by the National Institutes of Health (NIH) team as focusing on criteria for diagnosing the syndrome is neither Necessary and not sufficient. [0003] Ovarian androgen excess appears to arise most often from absolute or relative fat excess in adipose tissue, particularly the liver, which in turn leads...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/585A61K31/155A61K31/4439A61P1/16A61P43/00
CPCA61K31/155A61K31/4439A61K31/585A61P15/08A61K2300/00A61P1/16A61P43/00
Inventor 洛尔德斯·伊巴涅斯佛朗西斯·德杰埃尔
Owner UNIVERSITE CATHOLIQUE DE LOUVAIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap